

1 Title

2 **Sensitive and specific recombinase polymerase amplification set of assays for fast**
3 **screening, detection and identification of *Bacillus anthracis* in a field setting**

4 Running title

5 **Specific and fast RPA-identification of *B. anthracis***

6 Authors

7 Mostafa Bentahir^{1&2#}, Jérôme Ambroise¹, Cathy Delcorps², Paola Pilo³ and Jean-Luc Gala¹

8

9 1. Centre de Technologies Moléculaires Appliquées (CTMA), Institut de Recherche
10 Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.

11 2. Biothreats unit, Defense Laboratories Department (DLD), Belgian Armed Forces,
12 Brussels, Belgium.

13 3. Institute of Veterinary Bacteriology, Vetsuisse, University of Bern, 122
14 Laenggassstrasse, Postfach 3350 CH-3001, Bern, Switzerland

15

16 **# Mostafa Bentahir**

17 mostafa.bentahir@uclouvain.be

18 Centre de Technologies Moléculaires Appliquées, Université catholique de Louvain, Clos

19 Chapelle-aux-Champs, 30/46 1200 Brussels, Belgium.

20

21 Abstract

22 Four isothermal recombinase polymerase amplification assays (RPA) were developed for fast
23 in-field identification of *Bacillus (B.) anthracis*. RPAs targeted three specific sequences (i.e.
24 BA_5345 chromosomal marker, lethal factor *lef*-pXO1, and capsule biosynthesis *capA*-
25 pXO2), and a conserved sequence of the *B. cereus* group in the adenylate cyclase gene (*adk*).
26 *B. anthracis*-specific RPA assays were first tested on purified genomic DNAs (n=60)
27 containing 11 representatives of *B. anthracis*, then on soil (n=8) and white powder (n=8)
28 samples spiked with inactivated *B. anthracis* spores and/or other biological agents. The RPA
29 assays were also tested in another laboratory facility which blindly provided DNA and lysate
30 samples (n=30, including 20 *B. anthracis* strains). RPA tests displayed 100% specificity and
31 sensitivity. The hands-off turnaround time at 42°C ranged from 5 to 6 min for 10² genomic
32 copies. The analytical sensitivity of each RPA was ~10 molecules per reaction. Besides,
33 BA_5345 and *adk* RPA assays were assessed in field conditions on a series of surface swabs
34 (n=13 with 11 swabs contaminated with *B. thuringiensis* spores) and blindly dispatched to the
35 field laboratory by a CBRN sampling team. None of the 13 samples, except the control, tested
36 positive for *B. anthracis* and all samples harvested on spores-contaminated surfaces tested
37 positive with *adk*-RPA assay. All three *B. anthracis*-specific RPA assays proved suitable for
38 rapid and reliable identification of *B. anthracis* and could therefore easily be used by first
39 responders in field conditions to quickly discriminate between a deliberate release of *B.*
40 *anthracis* spores and a hoax attack involving “white-powders”.

41 Importance

42 In recent decades, particularly following 9/11 and the Amerithrax attack, the world
43 experienced several attempts to sow panic and chaos in the society through thousands of
44 white-powder copycats using household powders to mimic a real bioterrorism attack. In such
45 circumstances, field deployable detection methods are particularly needed to screen samples

collected from the scene. The aim is to test them directly using a fast and reliable assay for detecting the presence of *B. anthracis*. While this does not prevent further confirmatory tests to be performed in reference laboratories, it would bring useful, timely relevant information to the local crisis managers, and help them to take appropriate decisions without having to wait for qPCR results (turnaround time: few hours) or phenotypic identification and sequencing (turnaround time: few days). In the current investigation, we developed a set of isothermal RPA assays for a rapid screening and identification of *B. anthracis* in powders and soil samples with the purpose to discriminate a deliberate release of *B. anthracis* spores from a hoax attack involving “white-powders”. This would also apply to dispersion by spraying aerosolized forms of *B. anthracis*. Further work is now ongoing to confirm the first observations and validate the on-site use of these assays by first responders.

Introduction

B. anthracis, the etiological agent of anthrax, is a Gram positive endospore forming bacteria that can cause a life threatening disease in livestock and occasionally in humans (1). This zoonotic pathogen exerts its virulence activity through pXO1 and pXO2 plasmids carrying unique genes responsible for toxin production and capsule synthesis, respectively (2-4). Intentional dispersion of *B. anthracis* spores for bioterroristic purposes or in the context of military operations constitutes a major threat for both civilians and ground troops. In recent decades, particularly following 9/11 and the Amerithrax attack, the world experienced several attempts to sow panic and chaos in the society by a deliberate dispersion thousands of white-powder copycats using household powders to mimic a real bioterrorism attack (5-7). Under such circumstances, rapid and reliable detection and identification methods are particularly needed to fast screen samples collected from the scene, hence to test directly for the presence of *B. anthracis*. Conventional cultivation methods are clearly inappropriate in these conditions because they depend on highly skilled experts, require specific biosafety level 3 (BSL 3)

71 facilities and have a turnaround time of several hours or days (8). The high specificity,
72 sensitivity and speed of nucleic acid molecular methods, among which the quantitative real-
73 time polymerase chain reaction (qPCR), explain why these methods have become a
74 predominant diagnostic tool (9, 10). Besides, novel DNA-based technologies based on
75 isothermal amplification are now steadily gaining interest among first responders because of
76 their simplicity, speed and appropriateness for in-field use. Isothermal amplification enables
77 healthcare workers in remote locations to quickly analyze samples for the presence of nucleic
78 acid from a range of infectious agents, using field-deployable assays (11-15). Among these
79 methods, loop-mediated isothermal amplification (LAMP) (16) and recombinase polymerase
80 amplification (RPA) (17) assays have become increasingly popular and are now proposed in
81 the setting of bioterrorism for rapid biothreats detection including *B. anthracis* (18-20).

82 The major challenge for developing a *B. anthracis*-specific detection assay stems from the
83 genetic close relationship among a cluster of strains referred to as the *Bacillus cereus sensu*
84 *lato* group. This cluster comprises *B. anthracis*, *B. cereus*, *B. thuringiensis*, *B. mycoides*, *B.*
85 *pseudomycoides*, *B. weihenstephanensis* and *B. cytotoxicus* (21-23). The degree of genetic
86 similarity is substantially higher between *B. anthracis*, *B. cereus* and *B. thuringiensis*
87 compared to the other species. Some authors even proposed to consider them as a single
88 species (24). In that respect, the phylogenetic and taxonomic relationships of the bacteria of
89 the *B. cereus* group are still under intense discussion (25). To identify *B. anthracis*, PCR
90 assays commonly amplify target sequences from pXO1 and pXO2 virulence plasmids (10,
91 22). However, non-pathogenic *B. anthracis* isolates lacking these virulence plasmids as well
92 as few *B. cereus* strains harbouring anthrax-like plasmids have been characterized (6, 26).
93 These findings underscored the need for assays targeting unique chromosomal signatures
94 combined with plasmid genes to distinguish *B. anthracis* from closely related *B. cereus* group
95 isolates, and fully pathogenic from attenuated or non-virulent *B. anthracis* strains (27).

96 However, detecting *B. anthracis* chromosomal signatures sequences has proved to be very
97 challenging. Among all reported targets, only few were found to be unique to *B. anthracis*,
98 e.g. *purA* and *pclR* SNPs as well as BA_5345, *PL3* and BA5357 genes (9, 25).

99 We report here the design and validation of a set of three isothermal RPA assays that allows
100 for a fast and specific screening and identification of *B. anthracis* in powders and soil
101 samples. The assays amplify the BA_5345 chromosomal marker as well as *lef* (pXO1) and
102 *capA* (pXO2) virulence genes. The first validation was carried out on a well characterized
103 DNA collection of *B. anthracis* and *B. cereus* group members, and DNA strains outside the *B.*
104 *cereus* group. This was completed by a blind testing in an external laboratory facility, which
105 provided well-characterized DNA samples from its own collection of *B. anthracis* and *B.*
106 *cereus* group members. Optimized assays were subsequently used for detecting *B. anthracis*
107 in powder and soil samples spiked with inactivated *B. anthracis* spores and/or other biological
108 agents. A fourth RPA assay targeted a conserved sequence of *adk* gene which is shared
109 among all representatives of the *B. cereus* group. Finally, BA_5345 and *adk* RPA assays were
110 evaluated in field conditions by processing samples with and without *B. thuringiensis* strain, a
111 widely used simulant of *B. anthracis*. Data were compared to those obtained with our
112 previously validated duplex qPCR (28).

113 **Results**

114 **RPA assays optimization.** In the first optimization phase using the TwistAmp® Basic
115 amplification kit, three pairs of RPA primers targeting various sequence regions of BA_5345,
116 *lef*, *capA* and *adk* cloned target genes were selected based on the highest amplification
117 efficiency and a lowest background amplification on the gel electrophoresis (Figure 2). Unlike
118 set-1 and set-3 pairs of primers, the *lef* sequence region targeted by the set-2 pair of RPA

119 primers matched these criteria (Fig 2A). A similar approach was used to select the optimal
120 target region within the BA_5345, *capA* and *adk* sequences.

121 After the selection of the optimal target regions, optimization was carried out using the real-
122 time fluorescence DNA amplification TwistAmp® exo. RPA primers and probe were selected
123 according to the highest and fastest fluorescence amplification and negative NTC signals
124 (Table 1). The optimal temperature of the RPA reaction was set at 42°C. Following an initial
125 pre-incubation for 3 min, the tubes were taken out from the thermoblock, mixed vigorously,
126 spun and incubated further for the remaining period of time. Using 5×10^2 genomic copies of
127 each BA_5345, *lef*, *capA* and *adk* cloned target in optimal reaction conditions, the detection
128 threshold time was 5.3, 6.3, 4.7 and 5.3 min, respectively. RPA results with pXO1 (*lef*) and
129 pXO2 (*capA*) targets were concordant with those obtained with our duplex qPCR designed for
130 detecting the same plasmid sequences (28).

131 **RPA assays sensitivity and speed.** Analytical sensitivity was assessed under optimal
132 conditions on tenfold serial dilution of recombinant plasmid standards carrying the BA_5345,
133 *lef* or *capA* targets. Recombinant *adk* plasmid was not included in this assessment. For each
134 RPA assay, the concentration target of the DNA measured by fluorescence covered five
135 orders of magnitude (Fig 3A, 3B and 3C). The limit of detection (LOD) of each RPA assay at
136 a 95% detection probability, as estimated by a probit regression analysis on quintuplicate
137 tests, was 13.31, 11.61 and 7.43 molecules per reaction for BA-5345, *lef* and *capA*,
138 respectively (Fig 4A). The RPA assay showed excellent linearity over a dynamic range of 10^2
139 to 10^6 copies for each BA-5345, *lef* and *capA* target with a R-squared correlation of 0.97, 0.98
140 and 0.99, respectively (Fig 4B).

141 BA_5345, *lef* and *capA* RPA assays correctly identified *B. anthracis* reference DNAs (n=11),
142 powders containing a fixed concentration of *B. anthracis* Sterne spores (n=4) and soil samples

143 (n=3) spiked with different concentration of *B. anthracis* (Ames strain) spores with 100%
144 sensitivity (n=18). The mean detection time for *B. anthracis* reference DNAs was 4.37, 6.80
145 and 4.23 min, respectively. Data from three replicates were reproducible. It is of note that
146 powder samples spiked with *B. anthracis* spores were BA_5345- and *lef*-positive and *capA*-
147 negative, in accordance with the *B. anthracis* Sterne (pXO1 + pXO2 -) strain.

148 **RPA assays specificity and cross reactivity.** Specificity was evaluated on a panel of 50
149 reference DNAs from strains phylogenetically distant or very close to *B. anthracis*, 4 negative
150 powder, 5 soils spiked with single or multiple biological agents and 13 swab samples (with
151 (n=11) or without (n=2) *B. thuringiensis* spores) tested in field conditions. Pooled results from
152 all samples tested by RPA (n=72) indicated an overall specificity of 100 %. No non-specific
153 signal was generated with 50 non-*B. anthracis* strains among which closely related *B. cereus*
154 group, *Bacillus spp* and bacteria frequently encountered as contaminants during sampling. No
155 background signal was detected with human DNA. No cross-detection was observed for the
156 remaining samples containing either *B. thuringiensis* or other bacterial and viral biological
157 agents.

158 **Field testing**

159 The BA_5345 and *adk* RPA assays were finally assessed on 13 swab samples collected and
160 processed in field conditions under a laboratory tent. Data were compared to those obtained
161 with a duplex qPCR for detecting *B. anthracis purA* SNPs and *B. cereus* group *ptsI* common
162 marker (28) (Table 4). All swab samples, except the positive control, were negative with the
163 BA_5345-RPA and the *purA* qPCR assays (Table 4). Results obtained with *adk*-RPA were
164 identical to those generated by the *ptsI*-qPCR assay, except for sample 2 which was RPA-
165 positive but qPCR-negative (Table 4). This latter turned out positive when tested on diluted
166 extracted DNA.

167 **Blind testing in the Institute of Veterinary Bacteriology, Bern, Switzerland**

168 The three *B. anthracis* RPA-specific assays carried out on a panel of DNA and lysate samples
169 (n=30 among which 20 *B. anthracis* and 10 *B. cereus* group members) were provided by the
170 Institute of Veterinary Bacteriology and assessed in this facility. RPA results were 100%
171 concordant with previous strain characterizations (Table 5). *B. anthracis*-specific RPA tests
172 remained negative for all *B. cereus* DNA samples, which were efficiently amplified at
173 equivalent concentration by a PCR of *panC* gene carried out in parallel to RPA testing.

174 **Discussion**

175 In the event of a natural, accidental or deliberate dispersal of *B. anthracis* spores, there is a
176 crucial need for fast and reliable screening and detection of contaminated patients, animals,
177 environment, or surfaces to immediately initiate appropriate countermeasures (29, 30).
178 Overwhelming data published so far in this specific research area point out the lack of
179 methods readily usable by first responders for on-site detection of *B. anthracis* spores, and the
180 need for assays based on amplification of sequences from pXO1 and pXO2 virulence
181 plasmids combined with specific chromosomal markers (9, 10). In the current study,
182 isothermal amplification and detection were carried out on a set of DNA targets including
183 pXO1 (*lef*) and pXO2 (*capA*) plasmid virulence targets combined with BA_5345, which is
184 one of the most stable and specific chromosomal markers identified (31, 32). It is noteworthy
185 that a panel of ten RPA assays was previously tested for detecting biothreat agents including
186 *B. anthracis* (19). However, the focus was rather set on assay performance while *B. anthracis*
187 detection was restricted to both virulence plasmids. The aim of the current study was to
188 design a set of field-portable RPA assays usable in rapid diagnostic test (RDT), point of care
189 testing (POCT) or point-of-need (PAN). This multi-target approach allowed for fast and

190 specific screening of samples with the detection of *B. anthracis* and its discrimination from
191 closely related species belonging to the *Bacillus cereus sensu lato* group.

192 The current RPA assays were as sensitive as conventional qPCR with a LOD for each target
193 gene being as low as 10 genome-equivalent copies. In terms of sensitivity and specificity, the
194 current assays correctly identified all *B. anthracis* (11/11) among a panel of 60 reference
195 DNAs including *B. anthracis* closely related species with no cross detection. Regarding the
196 latter, it is of note that this panel included two *B. anthracis* phylogenetically-very close
197 neighbors that we recently isolated from a soil sample in Namibia and that was further
198 characterized by whole genome sequencing (manuscript in process). Moreover, the current
199 assays correctly identified soil and powder samples containing *B. anthracis* spores. Finally,
200 swab samples contaminated with *B. thuringiensis* used as *B. anthracis* simulant were rapidly
201 and correctly identified in field conditions using a previous version of these RPA assays based
202 only on BA_5345 and *adk* DNA targets.

203 Interestingly enough, as requested for a first screening and detection test, this RPA reaction
204 was completed in less than 4 to 7 min depending on the target. This is significantly faster than
205 conventional qPCR method with fluorescent probes which has a hands-off turnaround time of
206 ~1.5 h. It is also faster than other isothermal amplification methods, e.g. LAMP which
207 requires <45 min for signal build up (15, 19, 33). Moreover, RPA assays can be used on a
208 small (74 x 178 x 188 mm), light (weight: 1 kg) and user-friendly portable device. Moreover,
209 RPA kits are now commercially available in lyophilized format. Altogether, these assay
210 characteristics make it particularly suitable and appropriate to in-field screening of suspicious
211 materials like “white powders” and soil samples in suspected areas and for the detection of *B.*
212 *anthracis* contaminated samples or surfaces. For these purposes, current assays may well be
213 carried out in a van equipped with a glove box for sample inactivation and DNA extraction, as
214 well as a dedicated space for performing analytical work and data processing. We believe that

215 such a lean organization based on a ultra-light deployable laboratory with simple, fast and
216 robust screening tests would enable first responders to rapidly complete a first assessment,
217 hence to save precious time and resources in case of “white powder” hoaxes. Recent reports
218 highlighted the feasibility of this RPA-based RDT or POCT concept for detecting either
219 *leishmania donovani* using a suitcase laboratory (13), Ebola in Guinea (14), Dengue (15),
220 Chikungunya (11) or enteric viruses (12). Further work is now required to validate the current
221 set of RPA assays on a broader panel of soil and powder samples contaminated both with *B.*
222 *anthracis* spores and with closely related species, and to validate these assays during on-site
223 operations in the framework of international exercises.

224 Initial *adk*-RPA tests carried out with earlier RPA-exo kit batches appeared to be very specific
225 including when performed on-site during the exercise in Pionki, as reported in this work.
226 Results showed indeed unambiguously that *pst1*-qPCR and *adk*-RPA assay carried out in field
227 conditions provided similar results as qPCR, except for sample 2, which positivity was only
228 detected by RPA. The latter result underscored the occurrence of a PCR inhibition leading to
229 a false-negative result of the *pst1*-qPCR for this particular sample. RPA result obtained with
230 the latter sample indicates that this isothermal amplification assay was more robust and less
231 prone to matrix induced inhibition effects than qPCR (34). The potential of *adk* target gene to
232 discriminate *B. cereus* group strains from bacteria of other genera including *Bacillus spp.*
233 strains was also confirmed with a SYBR Green qPCR using the same primers as for the *adk*-
234 RPA assay (Table 2). However, despite these very promising initial RPA results, artefactual
235 amplification in NTC samples hampered further experiments.

236 In conclusion, three *B. anthracis*-specific RPA assays were developed for rapid and reliable
237 screening of environmental samples by first responders in field conditions on samples
238 commonly suspected to be contaminated by *B. anthracis* spores, i.e. suspicious white powders
239 and soils.

240 **Materials and methods**

241 **Bacterial strains and environmental samples.** A first panel of 60 reference bacterial strains
242 was used in this study comprising purified genomic DNA from 11 *B. anthracis*, 30 *B. cereus*
243 *sensu lato* group, 9 *Bacillus* spp., as well as 10 Gram-positive and Gram-negative strains of
244 other genera and human DNA. These purified genomic DNAs were obtained from the Centre
245 d'Etudes du Bouchet (Vert-le-petit, France), the Bundeswehr (Germany) and the collection of
246 the Microbiology Unit (Université Catholique de Louvain, Belgium). The latter institution
247 also kindly provided us with 22 additional strains of the *Bacillus cereus sensu lato* group and
248 8 *Bacillus* spp. Genomic DNAs of this panel of strains were characterized for the
249 presence/absence of the virulence plasmids pXO1 and pXO2 using a previously described
250 duplex qPCR (28).

251 A second sample collection tested in this study consisted of 8 soil and 8 powder
252 environmental reconstituted samples. Soil samples (2g) were spiked either with *B. anthracis*
253 Ames strain, Vaccinia virus, *B. thuringiensis*, *Francisella tularensis* Schu4 strain,
254 *Burkholderia pseudomallei* or a mix of *Francisella* and *Burkholderia* at a concentration
255 varying between 2×10^4 and 2×10^7 CFU/g of soil. Powder samples included DiPel®
256 biological insecticide, yeast, cream and baking soda were either spiked or not with *B.*
257 *anthracis* Sterne strain. Prior to spiking carried out at the US Army Dugway Proving Ground
258 facility, all biological agents were inactivated with cobalt gamma-irradiation. These
259 environmental samples were obtained in the frame of round robin SIBA (Sample
260 Identification of Biological Agents) exercises organized on February 2006 (soils samples)
261 and of January 2009 (powder samples) by the BioTesting & Production, Army Test &
262 Evaluation Center, Developmental Test Command, West Desert Test Center, Life Science
263 Test Facility, Dugway Proving Ground, UT 84022, USA for testing within the NATO Army

264 Armaments Group Joint Capability Group on CBRN Defence Group on *Sampling and*
265 *Identification of Chemical, Biological, and Radiological Agent* (SIBCRA – SG).

266 Another set of samples consisted of 13 swabs collected and analyzed on-site during the
267 PIONEX exercise organized in the framework of EC-FP7-PRACTICE project [European
268 Commission 7th framework programme, Preparedness and Resilience Against CBRN
269 Terrorism using Integrated Concepts and Equipment], from 22-25 April 2014, Pionki
270 (Warsaw), Poland ([https://www.practice-fp7-security.eu/cms,article,82,final-full-scale-civil-](https://www.practice-fp7-security.eu/cms,article,82,final-full-scale-civil-protection-cbrn-field-exercise-%7C-23-2....html)
271 [protection-cbrn-field-exercise-%7C-23-2....html](https://www.practice-fp7-security.eu/cms,article,82,final-full-scale-civil-protection-cbrn-field-exercise-%7C-23-2....html)) (35). One of the objectives of the exercise
272 was to test and validate rapid diagnostic tests usable in field conditions. In that respect, an
273 inflatable tent laboratory was deployed close to the scene to carry out DNA-based microbial
274 identification using qPCR and RPA (Figure 1, Pictures A-F). Two scenarios were executed by
275 Polish State Firemen CBRN sampling team: (a) swabbing barrels found with suspicious
276 substances in a nearby forest, and (b) swabbing surfaces contaminated by white powders after
277 intentional release inside a city building. After collection on site, samples were quickly
278 delivered to the laboratory. In the first scenario, swab samples (Table 4: samples n°1 to 3)
279 were processed for testing the presence of five different pathogens including the *B. anthracis*
280 simulant. In the second scenario, swab samples (Table 4, samples 4-13) were processed for
281 testing the presence of *B. anthracis*. In both scenarios, spores of *B. thuringiensis* ssp. *aizawai*,
282 strain ABTS-1857 (Xentari biological insecticide, Valent Biosciences Corporation, CA, USA)
283 were used as a *B. anthracis* simulant. Simulant and guidelines for contamination of both
284 scenes were provided by the CTMA/UCL laboratory staff and samples anonymized by the
285 PIONEX exercise controller.

286 The last validation of the RPA assays was carried out in the Department of Infectious
287 Diseases and Pathobiology, Institute of Veterinary Bacteriology, Bern, Switzerland where all
288 RPA reagents were shipped before hosting two scientists from CTMA (MB and JLG) for

289 carrying out the RPA assays. DNA samples from the Institute of Veterinary Bacteriology
290 collection were prepared for blind testing by a local staff member (PP). DNA samples
291 comprised *B. anthracis* (n= 20) and *B. cereus* (n= 10) group members (36-38). Whereas *B.*
292 *anthracis* were previously characterized for the *B. anthracis* markers Sap, cap/pXO2 and
293 pag/pXO1 (39). *B. cereus* DNA were assessed in parallel by the local scientist (PP) using the
294 end-point PCR targeting the *panC* gene (40).

295 **DNA extraction.** All strains were cultivated in the CTMA laboratory except for *B. anthracis*;
296 cultivated strains were extracted using the fully automated system EZ1 (Qiagen, The
297 Netherlands). DNA from powder samples and swabs were extracted using the NucliSens
298 miniMag semi-automated apparatus (Biomérieux Inc., Boxtel, The Netherlands). DNA from
299 spiked environmental soil samples was extracted using the PowerMax Soil DNA Isolation Kit
300 (Mo Bio Laboratories, Inc, Carlsbad, CA, USA). Extraction was carried out according to the
301 manufacturer's instructions and the resulting DNA was eluted in Tris-HCl buffer (pH 8) and
302 stored at -20°C. The DNA extractions performed at the Institute of Veterinary Bacteriology in
303 Bern were performed with the DNeasy blood & tissue kit (Qiagen, Hilden, Germany)
304 according to the manufacturer's instructions. Lysates were carried out as previously described
305 (38).

306 **RPA assays design.** Three RPA assays were designed to detect and identify *B. anthracis* with
307 a high specificity so as to distinguish it from closely related *B. cereus* pathogenic and non-
308 pathogenic strains. These assays targeted the specific *B. anthracis* genomic marker BA_5345
309 (GenBank CP009981), together with the *lef* (GenBank CP009980) and *capA* (GenBank
310 CP009979) genes located respectively on pXO1 and pXO2 virulence plasmids. A fourth assay
311 targeted a highly conserved region of *adk* gene (GenBank CP009981), which is common to *B.*
312 *cereus* group strains as deduced from a multiple sequence alignment performed on Genbank
313 available *adk* sequences (41, 42). The sequence and localization of primers and probes used

314 for each RPA assay and the expected size of RPA amplicons are depicted in Table 1.
315 Positions were numbered according to the reference genomic sequence of *B. anthracis* strain
316 Ames_BA1004 (Table 1). The length of RPA primers and probes was set to 30-35 and ~45
317 nucleotides, respectively. Each probe was designed by introducing a THF abasic nucleotide
318 analogue (tetrahydrofuran) at position 30 flanked by dT-FAM fluorophore (5-
319 Carboxyfluorescein) and dT-BHQ1 quencher (black hole quencher) at position 28 and 32,
320 respectively (Table 1). RPA primers and probes were designed based on rules and guidelines
321 provided by the manufacturer, and purchased from Eurogentec (Liège, Belgium). The
322 specificity of the primers and probes against their specific targets was studied in silico using
323 Blast search tool as well as the Biostrings R package. The latter was used to identify a perfect
324 match with whole- genome sequence of *B. anthracis* and closely related species (*B. cereus*, *B.*
325 *thuringensis*, *B. mycoides*, *B. cytotoxicus* and *B. weihenstephanensis*) which are available on
326 genbank (n total = 171).

327 **RPA assays conditions optimization.** Initial optimization was carried out using the
328 TwistAmp® Basic kit (TwistDx Limited, Cambridge, United Kingdom). A gel
329 electrophoresis analysis was carried out after amplification with tested primers in order to
330 improve the yield of amplification through selection of optimal target sequences. The final set
331 of primers was selected based on the highest amplification efficiency and negative or lowest
332 NTC value. After the selection of optimal target regions, a second phase of assay optimization
333 was carried out using the real-time fluorescence DNA amplification TwistAmp® exo kit from
334 the same manufacturer. The RPA reaction was performed in a final volume of 50 µL
335 containing 420 nM each RPA primer, 120 nM RPA probe except for *lef*-probe that was 60
336 nM, 14 mM Mg-acetate and 1x rehydration buffer. All reagents except tested DNA sample
337 and Mg-acetate were prepared in master mix, which was distributed into 0.2 ml reaction tube
338 containing a dried enzyme pellet. A volume of 5 µL of sample DNA (5 pg) or control

339 standard was added to the tube. Next, Mg-acetate was pipetted into the tube lids. The lids
340 were closed, the Mg-acetate was centrifuged into the tubes using a minispin centrifuge, and
341 the tubes were immediately placed into a Twista portable real-time fluorometer (TwistDx,
342 Cambridge, UK). Fluorescence measurements in the FAM channel were carried out at 42°C
343 every 20 s for 20 min. To distinguish positive from negative results, a cutoff value was
344 calculated for every individual sample according to the guidelines on threshold validation in
345 the Twista Studio software manual. A sample was deemed positive if all replicates were
346 above three standard deviations (3 SD) of the background during a defined time range (i.e.,
347 after 19 to 20 min of amplification). In addition, the slope validation was also carried out
348 according to the guidelines.

349 **Real-time PCR.** Two duplex qPCRs described previously were used to identify *B. anthracis*
350 and to distinguish *B. cereus* group strains from other species (28). The first qPCR was based
351 on *purA* and *ptsI* targets while the second allowed detection of the *B. anthracis* virulence
352 plasmids pXO1 and pXO2. A SYBR®-Green qPCR was developed to detect the *adk* target
353 gene. This qPCR assay was carried out in 25 µL reaction volume containing 12.5 µL of 2X
354 power SYBR Green master mix (Life technologies, Carlsbad, California, USA), 165 nM each
355 primer and 2,5 µL of tested genomic DNA. The reaction was initiated at 50°C for 2 min, and
356 95°C for 10 min followed by 45 cycles of denaturation at 95°C for 15 s and annealing at 63°C
357 for 1 min and extension for 90 seconds at 72°C. Each sample was tested in triplicate and data
358 were recorded as Cycle threshold (Ct) on a Biorad CFX96 Detection System (Bio-Rad
359 Laboratories N.V., Temse, Belgium) using the analytical software from the same
360 manufacture.

361 **Plasmid DNA and calibration curves.** The *lef*, *capA*, BA_5345 and *adk* genes were
362 amplified by PCR using specific pair of primers (Table 1) and genomic DNA from *B.*
363 *anthracis* 9774 strain. Primers were designed using Primer 3 algorithm (43). Each reaction

364 PCR mixture (50 μ l) contained 1 ng of genomic DNA, 250 nM each primer, 250 μ M each
365 desoxynucleoside triphosphate (dNTP), 1.5 mM $MgCl_2$, 0.7 U/reaction *ampliTaq* polymerase
366 and 1X *ampliTaq* buffer II (Roche Molecular Systems, New Jersey, USA). The thermal
367 amplification profile consisted of a denaturation step at 94°C for 3 min followed by 35 cycles
368 thermal cycling at 94°C for 30 sec, 55 °C for 30 sec, and 72°C for 45 sec. After cycling,
369 reaction tubes were further maintained at 72°C for 7 min. PCR products were purified using
370 QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany), ligated into pCR®4-TOPO® and
371 transformed in One Shot® TOP10 Electrocompetent *E. coli* bacterial cells using TOPO TA
372 Cloning® Kit for Sequencing (Life technologies, Carlsbad, CA, USA). Resulting recombinant
373 plasmids were purified using Invisorb® Spin Plasmid Mini Two (Invitek, Berlin, Germany)
374 and verified by sequencing with a BigDye® Terminator v1.1 Cycle Sequencing kit (Applied
375 Biosystems, USA), using an automated sequencer (3130 Genetic Analyser, Applied
376 Biosystems). The BA_5345, *lef* and *capA* recombinant plasmids were quantified by UV with
377 a NanoDrop® ND-1000 v3.5.2 spectrophotometer (Isogen Life Science, The Netherlands).
378 Calibration curves were created from 10-fold diluted recombinant plasmids with a range of
379 10^6 down to 10^0 copies per reaction as calculated from plasmid concentration (OD 260 nm).
380 The BA_5345, *lef* and *capA* gene plasmid standards were tested in five replicates, the
381 threshold time in minutes was plotted against the number of molecules detected.

382 **Statistical analysis of sensitivity.** The LOD was determined using a probit-analysis. For each
383 assay, a probit regression model was fitted with the “glm” function of the R statistical
384 software (<http://www.r-project.org/>) using the target concentration as the independent variable
385 and the detection event as the response variable. Each probit regression model was then used
386 to determine the lowest concentration enabling target detection with a 95% probability (i.e.
387 the LOD).

388 **Acknowledgments**

389 We thank the Bundeswehr (Germany), the Centre d'Etudes du Bouchet (Vert-le-petit, France)
390 and the team food and environmental microbiology of Prof. Jacques Mahillon for providing
391 us with *Bacillus anthracis* reference DNA and *Bacillus* sp. reference strains used in the
392 current study. We are grateful to Dr. Anne-Sophie Piette who carried out in-field RPA
393 experiments and also to the members of CTMA deployable capacity who took part of the
394 PIONEX exercise. We also thank Pr. Vincent Perreten from Institute of Veterinary
395 Bacteriology for providing us with lysates of *B. anthracis* strains isolated in Africa. The
396 authors thank Dr. Leonid Irengue for fruitful discussions. This project was funded by the
397 Department Management of Scientific and Technological Research of Defence (IRSD-RSTD,
398 Royal High Institute for Defence) supporting research and development (*Bacillus anthracis*
399 detection expertise study) and Project B-LiFE: Biological Light Fieldable Laboratory for
400 Emergencies, European Space Agency (ESA), IAP-ARTES project.

401 **Author contributions**

402 Conceived and designed the experiments: MB. Performed the experiments and analyzed the
403 data: CD, MB, PP and JLG. Carried out the statistical analysis and manuscript revision: JA.
404 Wrote the paper: MB and JLG.

405 **References**

- 406 1. Spencer RC. 2003. *Bacillus anthracis*. J Clin Pathol 56:182-7.
- 407 2. Okinaka RT, Cloud K, Hampton O, Hoffmaster AR, Hill KK, Keim P, Koehler TM,
408 Lamke G, Kumano S, Mahillon J, Manter D, Martinez Y, Ricke D, Svensson R, Jackson PJ.
409 1999. Sequence and organization of pXO1, the large *Bacillus anthracis* plasmid harboring the
410 anthrax toxin genes. J Bacteriol 181:6509-15.
- 411 3. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. 1985. Demonstration of a
412 capsule plasmid in *Bacillus anthracis*. Infect Immun 49:291-7.
- 413 4. Frankel AE, Kuo SR, Dostal D, Watson L, Duesbery NS, Cheng CP, Cheng HJ,
414 Leppla SH. 2009. Pathophysiology of anthrax. Front Biosci (Landmark Ed) 14:4516-24.

- 415 5. Lim DV, Simpson JM, Kearns EA, Kramer MF. 2005. Current and developing
416 technologies for monitoring agents of bioterrorism and biowarfare. *Clin Microbiol Rev*
417 18:583-607.
- 418 6. Hoffmaster AR, Fitzgerald CC, Ribot E, Mayer LW, Popovic T. 2002. Molecular
419 subtyping of *Bacillus anthracis* and the 2001 bioterrorism-associated anthrax outbreak, United
420 States. *Emerg Infect Dis* 8:1111-6.
- 421 7. Centers for Disease C, Prevention. 2001. Update: Investigation of bioterrorism-related
422 anthrax and interim guidelines for exposure management and antimicrobial therapy, October
423 2001. *MMWR Morb Mortal Wkly Rep* 50:909-19.
- 424 8. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM,
425 Hauer J, McDade J, Osterholm MT, O'toole T. 1999. Anthrax as a biological weapon: medical
426 and public health management. *Jama* 281:1735-1745.
- 427 9. Kim J, Gedi V, Lee SC, Cho JH, Moon JY, Yoon MY. 2015. Advances in Anthrax
428 Detection: Overview of Bioprobes and Biosensors. *Appl Biochem Biotechnol* 176:957-77.
- 429 10. Ireng LM, Gala JL. 2012. Rapid detection methods for *Bacillus anthracis* in
430 environmental samples: a review. *Appl Microbiol Biotechnol* 93:1411-22.
- 431 11. Patel P, Abd El Wahed A, Faye O, Pruger P, Kaiser M, Thaloengsok S, Ubol S,
432 Sakuntabhai A, Leparco-Goffart I, Hufert FT, Sall AA, Weidmann M, Niedrig M. 2016. A
433 Field-Deployable Reverse Transcription Recombinase Polymerase Amplification Assay for
434 Rapid Detection of the Chikungunya Virus. *PLoS Negl Trop Dis* 10:e0004953.
- 435 12. Moore MD, Jaykus LA. 2017. Development of a Recombinase Polymerase
436 Amplification Assay for Detection of Epidemic Human Noroviruses. *Sci Rep* 7:40244.
- 437 13. Mondal D, Ghosh P, Khan MA, Hossain F, Bohlken-Fascher S, Matlashewski G,
438 Kroeger A, Oliaro P, Abd El Wahed A. 2016. Mobile suitcase laboratory for rapid detection
439 of *Leishmania donovani* using recombinase polymerase amplification assay. *Parasit Vectors*
440 9:281.
- 441 14. Faye O, Faye O, Soropogui B, Patel P, El Wahed AA, Loucoubar C, Fall G, Kiory D,
442 Magassouba N, Keita S, Konde MK, Diallo AA, Koivogui L, Karlberg H, Mirazimi A,
443 Nentwich O, Piepenburg O, Niedrig M, Weidmann M, Sall AA. 2015. Development and
444 deployment of a rapid recombinase polymerase amplification Ebola virus detection assay in
445 Guinea in 2015. *Euro Surveill* 20.
- 446 15. Abd El Wahed A, Patel P, Faye O, Thaloengsok S, Heidenreich D, Matangkasombut
447 P, Manopwisedjaroen K, Sakuntabhai A, Sall AA, Hufert FT, Weidmann M. 2015.
448 Recombinase Polymerase Amplification Assay for Rapid Diagnostics of Dengue Infection.
449 *PLoS One* 10:e0129682.
- 450 16. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T.
451 2000. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* 28:E63.

- 452 17. Piepenburg O, Williams CH, Stemple DL, Armes NA. 2006. DNA detection using
453 recombination proteins. *PLoS biology* 4:e204.
- 454 18. Hatano B, Maki T, Obara T, Fukumoto H, Hagsisawa K, Matsushita Y, Okutani A,
455 Bazartseren B, Inoue S, Sata T, Katano H. 2010. LAMP using a disposable pocket warmer for
456 anthrax detection, a highly mobile and reliable method for anti-bioterrorism. *Jpn J Infect Dis*
457 63:36-40.
- 458 19. Euler M, Wang Y, Heidenreich D, Patel P, Strohmeier O, Hakenberg S, Niedrig M,
459 Hufert FT, Weidmann M. 2013. Development of a panel of recombinase polymerase
460 amplification assays for detection of biothreat agents. *J Clin Microbiol* 51:1110-7.
- 461 20. Dugan L, Bearinger J, Hinckley A, Strout C, Souza B. 2012. Detection of *Bacillus*
462 anthracis from spores and cells by loop-mediated isothermal amplification without sample
463 preparation. *J Microbiol Methods* 90:280-4.
- 464 21. Read TD, Peterson SN, Tourasse N, Baillie LW, Paulsen IT, Nelson KE, Tettelin H,
465 Fouts DE, Eisen JA, Gill SR, Holtzapple EK, Okstad OA, Helgason E, Rilstone J, Wu M,
466 Kolonay JF, Beanan MJ, Dodson RJ, Brinkac LM, Gwinn M, DeBoy RT, Madpu R,
467 Daugherty SC, Durkin AS, Haft DH, Nelson WC, Peterson JD, Pop M, Khouri HM, Radune
468 D, Benton JL, Mahamoud Y, Jiang L, Hance IR, Weidman JF, Berry KJ, Plaut RD, Wolf AM,
469 Watkins KL, Nierman WC, Hazen A, Cline R, Redmond C, Thwaite JE, White O, Salzberg
470 SL, Thomason B, Friedlander AM, Koehler TM, Hanna PC, et al. 2003. The genome
471 sequence of *Bacillus anthracis* Ames and comparison to closely related bacteria. *Nature*
472 423:81-6.
- 473 22. Ivanova N, Sorokin A, Anderson I, Galleron N, Candelon B, Kapatal V,
474 Bhattacharyya A, Reznik G, Mikhailova N, Lapidus A, Chu L, Mazur M, Goltsman E, Larsen
475 N, D'Souza M, Walunas T, Grechkin Y, Pusch G, Haselkorn R, Fonstein M, Ehrlich SD,
476 Overbeek R, Kyrpides N. 2003. Genome sequence of *Bacillus cereus* and comparative
477 analysis with *Bacillus anthracis*. *Nature* 423:87-91.
- 478 23. Guinebretière M-H, Auger S, Galleron N, Contzen M, De Sarrau B, De Buyser M-L,
479 Lamberet G, Fagerlund A, Granum PE, Lereclus D. 2013. *Bacillus cytotoxicus* sp. nov. is a
480 novel thermotolerant species of the *Bacillus cereus* Group occasionally associated with food
481 poisoning. *International journal of systematic and evolutionary microbiology* 63:31-40.
- 482 24. Helgason E, Okstad OA, Caugant DA, Johansen HA, Fouet A, Mock M, Hegna I,
483 Kolsto AB. 2000. *Bacillus anthracis*, *Bacillus cereus*, and *Bacillus thuringiensis*--one species
484 on the basis of genetic evidence. *Appl Environ Microbiol* 66:2627-30.
- 485 25. Liu Y, Lai Q, Goker M, Meier-Kolthoff JP, Wang M, Sun Y, Wang L, Shao Z. 2015.
486 Genomic insights into the taxonomic status of the *Bacillus cereus* group. *Sci Rep* 5:14082.
- 487 26. Hoffmaster AR, Hill KK, Gee JE, Marston CK, De BK, Popovic T, Sue D, Wilkins
488 PP, Avashia SB, Drumgoole R, Helma CH, Ticknor LO, Okinaka RT, Jackson PJ. 2006.
489 Characterization of *Bacillus cereus* isolates associated with fatal pneumonias: strains are

- 490 closely related to *Bacillus anthracis* and harbor *B. anthracis* virulence genes. *J Clin Microbiol*
491 44:3352-60.
- 492 27. Klee SR, Nattermann H, Becker S, Urban-Schriefer M, Franz T, Jacob D, Appel B.
493 2006. Evaluation of different methods to discriminate *Bacillus anthracis* from other bacteria
494 of the *Bacillus cereus* group. *J Appl Microbiol* 100:673-81.
- 495 28. Irengue LM, Durant JF, Tomaso H, Pilo P, Olsen JS, Ramisse V, Mahillon J, Gala JL.
496 2010. Development and validation of a real-time quantitative PCR assay for rapid
497 identification of *Bacillus anthracis* in environmental samples. *Appl Microbiol Biotechnol*
498 88:1179-92.
- 499 29. Franz DR. 2009. Preparedness for an anthrax attack. *Mol Aspects Med* 30:503-10.
- 500 30. Cohen HW, Gould RM, Sidel VW. 2004. The pitfalls of bioterrorism preparedness:
501 the anthrax and smallpox experiences. *Am J Public Health* 94:1667-71.
- 502 31. Antwerpen MH, Zimmermann P, Bewley K, Frangoulidis D, Meyer H. 2008. Real-
503 time PCR system targeting a chromosomal marker specific for *Bacillus anthracis*. *Mol Cell*
504 *Probes* 22:313-5.
- 505 32. Agren J, Hamidjaja RA, Hansen T, Ruuls R, Thierry S, Vigre H, Janse I, Sundstrom
506 A, Segerman B, Koene M, Lofstrom C, Van Rotterdam B, Derzelle S. 2013. In silico and in
507 vitro evaluation of PCR-based assays for the detection of *Bacillus anthracis* chromosomal
508 signature sequences. *Virulence* 4:671-85.
- 509 33. Euler M, Wang Y, Otto P, Tomaso H, Escudero R, Anda P, Hufert FT, Weidmann M.
510 2012. Recombinase polymerase amplification assay for rapid detection of *Francisella*
511 *tularensis*. *J Clin Microbiol* 50:2234-8.
- 512 34. Francois P, Tangomo M, Hibbs J, Bonetti EJ, Boehme CC, Notomi T, Perkins MD,
513 Schrenzel J. 2011. Robustness of a loop-mediated isothermal amplification reaction for
514 diagnostic applications. *FEMS Immunol Med Microbiol* 62:41-8.
- 515 35. Vybornova OaG, J.L. 2018. Operations management and decision making in
516 deployment of an on-site biological analytical capacity *In* Moynihan G (ed), In press.
- 517 36. Pilo P, Rossano A, Bamanga H, Abdoukadi S, Perreten V, Frey J. 2011. Bovine
518 *Bacillus anthracis* in Cameroon. *Applied and environmental microbiology* 77:5818-5821.
- 519 37. Pilo P, Perreten V, Frey J. 2008. Molecular epidemiology of *Bacillus anthracis*:
520 determining the correct origin. *Applied and environmental microbiology* 74:2928-2931.
- 521 38. Maho A, Rossano A, Hächler H, Holzer A, Schelling E, Zinsstag J, Hassane MH,
522 Toguebaye BS, Akakpo AJ, Van Ert M. 2006. Antibiotic susceptibility and molecular
523 diversity of *Bacillus anthracis* strains in Chad: detection of a new phylogenetic subgroup.
524 *Journal of clinical microbiology* 44:3422-3425.

- 525 39. Ryu C, Lee K, Yoo C, Seong WK, Oh HB. 2003. Sensitive and rapid quantitative
526 detection of anthrax spores isolated from soil samples by real-time PCR. *Microbiol Immunol*
527 47:693-9.
- 528 40. Candelon B, Guilloux K, Ehrlich SD, Sorokin A. 2004. Two distinct types of rRNA
529 operons in the *Bacillus cereus* group. *Microbiology* 150:601-11.
- 530 41. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the
531 sensitivity of progressive multiple sequence alignment through sequence weighting, position-
532 specific gap penalties and weight matrix choice. *Nucleic Acids Res* 22:4673-80.
- 533 42. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis
534 program for Windows 95/98/NT, p 95-98. *In* (ed), [London]: Information Retrieval Ltd.,
535 c1979-c2000.,
- 536 43. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG.
537 2012. Primer3--new capabilities and interfaces. *Nucleic Acids Res* 40:e115-e115.

538 **Figure legend**

539 Figure 1. Main steps carried out in a laboratory tent in field for samples processing from
540 receipt to the final analyses. Laboratory tent as deployed in the field (A). Samples were
541 brought to the laboratory by the Polish State Firemen CBRN sampling team (B). Samples
542 were processed in a glovebox to inactivate potential bio-agents present in the sample (C and
543 D) and nucleic acids were then extracted outside the glovebox (E). qPCR and RPA assays
544 were carried out and data analyzed (F).

545 Figure 2. The RPA assay optimization was achieved using TwistAmp basic amplification kit
546 as illustrated for the *lef* target gene. The upper part (A) shows the relative position of RPA
547 pair of primers (set-1 to 3) used in screening as well as the part of the target where the *lef*
548 probe was designed. The lower part (B) shows the results of gel electrophoresis analysis
549 following target amplification with the indicated set of primers. Samples 1 and 2 correspond
550 to NTC prepared in pre- and post-PCR rooms while sample 3 contained the target DNA.

551 Figure 3. RPA Amplification plots. Amplification carried out on 10 fold serial dilution
552 standards including NTC samples of BA_5345 (A), *lef* (B) and *capA* (C) target sequences.

553 Figure 4. Analytical sensitivity and quantitative range of BA_5345, *lef* and *capA* RPA assays.
554 Limit of detection (LOD) as determined by probit regression analysis (A) and assays linearity
555 range (B).

556 Tables

557 Table 1: primers and probes used in this study

Type	Target	Name	Sequence (5'-3')	Start	End	Size (base)	amplicon size
PCR-primers	<i>lef</i>	lef-For	CGCTTCATTGTCTCTCCATAC	139956	139935	22	860
		lef-Rev	CAACCCCTAGTGCGGATTTAG	139097	139117	21	
	<i>capA</i>	capA-For	GGTACAACGTACAGAAGCAGT	18512	18532	21	971
		capA-Rev	GAGCACCCCTGGATGTATCTTT	19482	19461	22	
	BA_5345	BA-For	CGATTTTGTGGATTGCGTATG	4873856	4873876	21	493
		BA-Rev	ACCGCAAGTTGAATAGCAAG	4874348	4874329	20	
	<i>adk</i>	adk-For	CCGAACAGATTGTTGCCAAG	4360272	4360253	20	600
		adk-Rev	ACGCTAAGCCTCCGATGAGA	4359673	4359692	20	
RPA-primers	<i>lef</i>	lef-58-For	TTAGAATTGTAACTAAATCAGATTGGTTCT	139889	139859	31	146
		lef-60-Rev	CGTTCTATATTACTCCATGGACCTTCAAA	139744	139772	29	
	<i>capA</i>	capA-45-For	CGGATTATGGTGCTAAGGGAACATAAGATAC	18838	18868	31	145
		CapA-63-Rev	CCAAGAGTAGCAACCTAACACCATTTAC	18982	18954	29	
	BA_5345	BA-31-For	GTCCTGGCACATGGTACTACTCAACAAGAT	4874134	4874163	30	105
		BA-36-Rev	GAACAATGACCCTAGTGCATGTGTAGTTCC	4874238	4874209	30	
	<i>adk</i>	adk-27-For	GTGTGCGATAAATGTGGTGGCAATTATATCAAC	4359877	4359844	34	137
		adk-28-Rev	CTTTGTAGGTAACCAAGCTCCTCGTAGAAATCAAG	4359741	4359775	35	
Probes	<i>lef</i>	lef-exo-55	AATTTGTAATAATCAGATTGGTTCTTATCTAATAGATATCCAG	139885	139841	45	
	<i>capA</i>	capA-exo-56	AAGGCCTTTAAGAAGCTGATCTTGACTATGTGGGTGCTGGTGAA	18873	18917	45	
	BA_5345	BA-exo-54	CTCAACAAGATTCAGAGACTCGTACATACATAGAAGGACGATAC	4874152	4874196	45	
	<i>adk</i>	adk-exo-53	TGATGACAATGAAGAACTGTAGCAATCGCTTAGATGTAAATATTA	4359839	4359793	47	

558

559 Table 2: Bacterial strains used for testing RPA assays specificity and sensitivity

^a Name	Original identification	Source	RPA results (detection time in min)			qPCR results	
			BA_5345	lef (pXO1)	capA (pXO2)	adk	pXO1/pXO2
<i>B. anthracis</i>	9508	CEB	4,57 ± 0,23	6,80 ± 0,17	4,30 ± 0,00	+	+/+
<i>B. anthracis</i>	9531	CEB	4,20 ± 0,17	-	-	+	-/-
<i>B. anthracis</i>	9774	CEB	4,53 ± 0,40	6,23 ± 0,40	4,77 ± 0,40	+	+/+
<i>B. anthracis</i>	9506	CEB	4,10 ± 0,17	6,10 ± 0,17	4,67 ± 0,35	+	+/+
<i>B. anthracis</i>	9534	CEB	4,10 ± 0,17	-	4,67 ± 0,35	+	-/+
<i>B. anthracis</i>	9439	CEB	4,20 ± 0,17	6,53 ± 0,40	-	+	+/-
<i>B. anthracis</i>	9602	CEB	4,43 ± 0,51	6,43 ± 0,23	4,43 ± 0,23	+	+/+
<i>B. anthracis</i>	9440	CEB	4,30 ± 0,00	8,20 ± 0,17	4,57 ± 0,23	+	+/+
<i>B. anthracis</i>	VAR06/7570.4CAP	UCL	4,57 ± 0,23	7,00 ± 0,30	3,57 ± 0,23	+	+/+
<i>B. anthracis</i>	VAR06/1106.3#2	UCL	4,57 ± 0,23	6,90 ± 0,17	3,43 ± 0,23	+	+/+
<i>B. anthracis</i>	VAR06/5348.3#1	UCL	4,70 ± 0,00	7,00 ± 0,00	3,67 ± 0,35	+	+/+
<i>B. cereus</i>	ATCC 14579	UCL	-	-	-	+	-/-
<i>B. cereus</i>	ATCC 10987	UCL	-	-	-	+	-/-
<i>B. cereus</i>	DSM 2302	UCL	-	-	-	+	-/-
<i>B. cereus</i>	DSM345	BW	-	-	-	+	-/-
<i>B. cereus</i>	S3A	CTMA	-	-	-	+	-/-
<i>B. cereus</i>	ATCC 13061 (HT1-A1)	UCL	-	-	-	+	-/-
<i>B. cereus</i>	ATCC 10876 (HT1-A2)	UCL	-	-	-	+	-/-
<i>B. cereus</i>	ATCC 21282 (HT1-C1)	UCL	-	-	-	+	-/-
<i>B. mycoides</i>	MYC005	UCL	-	-	-	+	-/-
<i>B. mycoides</i>	ATCC 6463	UCL	-	-	-	+	-/-
<i>B. mycoides</i>	MYC003	UCL	-	-	-	+	-/-
<i>B. mycoides</i>	WSBC 10211	BW	-	-	-	+	-/-
<i>B. mycoides</i>	HBS 1-16	UCL	-	-	-	+	-/-
<i>B. pseudomycoides</i>	NRRL B-617	UCL	-	-	-	+	-/-
<i>B. pseudomycoides</i>	NRRL BD5	UCL	-	-	-	+	-/-
<i>B. pseudomycoides</i>	NRRL NRS 321N	UCL	-	-	-	+	-/-
<i>B. pseudomycoides</i>	6.A.3	CTMA	-	-	-	+	-/-
<i>B. weihenstephanensis</i>	WSBC 28005	BW	-	-	-	+	-/-
<i>B. weihenstephanensis</i>	WSBC 10204	UCL	-	-	-	+	-/-
<i>B. weihenstephanensis</i>	WSBC 10278	BW	-	-	-	+	-/-
<i>B. weihenstephanensis</i>	WSBC10207	UCL	-	-	-	+	-/-
<i>B. weihenstephanensis</i>	WS2481	UCL	-	-	-	+	-/-
<i>B. weihenstephanensis</i>	WSBC10201	UCL	-	-	-	+	-/-
<i>B. thuringiensis</i>	4Q2-72	UCL	-	-	-	+	-/-
<i>B. thuringiensis</i>	T03A016 = HD1	UCL	-	-	-	+	-/-
<i>B. thuringiensis</i>	WSBC 10206	BW	-	-	-	+	-/-
<i>B. thuringiensis</i>	ABTS-1857	CTMA	-	-	-	+	-/-
<i>B. thuringiensis</i>	HD73	UCL	-	-	-	+	-/-
<i>B. thuringiensis</i>	Bt5	UCL	-	-	-	+	-/-

<i>B. thuringiensis</i>	ATCC 39646	UCL	-	-	-	+	-/-
<i>B. subtilis</i>	ATCC 6633	UCL	-	-	-	-	-/-
<i>B. subtilis</i>	ATCC 12711	UCL	-	-	-	-	-/-
<i>B. subtilis</i>	ATCC 6051	UCL	-	-	-	-	-/-
<i>B. subtilis</i>	168 (Suxia)	UCL	-	-	-	-	-/-
<i>B. subtilis</i>	DSMZ 5934	CTMA	-	-	-	-	-/-
<i>B. amyloliquefaciens</i>	ATCC 23350	UCL	-	-	-	-	-/-
<i>B.adius</i>	ATCC 14574	UCL	-	-	-	-	-/-
<i>B. sphaericus</i>	ATCC 10208	UCL	-	-	-	-	-/-
<i>B. atrophaeus</i>	ATCC 9372	CTMA	-	-	-	-	-/-
<i>Streptococcus pyogenes</i>	ATCC 12344	CTMA	-	-	-	-	-/-
<i>Enterococcus faecalis</i>	ATCC 29212	CTMA	-	-	-	-	-/-
<i>Stenotrophomonas maltophilia</i>	ATCC 13637	CTMA	-	-	-	-	-/-
<i>Escherichia coli</i>	DSMZ 8579	CTMA	-	-	-	-	-/-
<i>Enterobacter aerogenes</i>	DSMZ 30053	CTMA	-	-	-	-	-/-
<i>Serratia liquefaciens</i>	ATCC 27592	CTMA	-	-	-	-	-/-
<i>Staphylococcus aureus</i>	NCTC 10442	CTMA	-	-	-	-	-/-
<i>Streptococcus pneumoniae</i>	DSMZ 20566	CTMA	-	-	-	-	-/-
<i>Klebsiella pneumoniae</i>	ATCC 13883	CTMA	-	-	-	-	-/-
<i>Clostridium difficile</i>	DSMZ 1296	CTMA	-	-	-	-	-/-

560 *BW* Bundeswehr (Germany), *CEB* Centre d'Etude du Bouchet (France), *UCL* Université Catholique de Louvain (Belgium), *CTMA* Centre de

561 Technologies Moléculaires Appliquées (Belgium). – not detected, + detected. ^aAfter extraction and measurement of DNA concentration, 5 pg

562 were used in each RPA reaction and samples with negative result were amplified in parallel using a 16S rRNA PCR.

563

564 Table 3 : Environmental powder and soil samples (NATO SIBCRA exercise)

Sample	matrix	spiking status	Concentration	RPA results		
				BA_5345	<i>lef</i> (pXO1)	<i>capA</i> (pXO2)
^b 01	Dipel powder	<i>B. thuringiensis</i>	ND	-	-	-
02	Dipel powder	<i>B. thuringiensis</i> + <i>B. anthracis</i> Sterne	ND	+	+	-
^b 03	Backing soda powder	Nihil	ND	-	-	-
04	Backing soda powder	<i>B. anthracis</i> Sterne	ND	+	+	-
^b 05	Yeast powder	Nihil	ND	-	-	-
06	Yeast powder	<i>B. anthracis</i> Sterne	ND	+	+	-
^b 07	Cream powder	Nihil	ND	-	-	-
08	Cream powder	<i>B. anthracis</i> Sterne	ND	+	+	-
09	Soil	<i>B. anthracis</i>	(2X10 ⁴ cfu/g)	+	+	+
10	Soil	<i>B. anthracis</i>	(2X10 ⁵ cfu/g)	+	+	+
11	Soil	<i>B. anthracis</i>	(2X10 ⁷ cfu/g)	+	+	+
12	Soil	<i>B. thuringiensis</i>	10 mg/g	-	-	-
13	Soil	<i>Vaccinia virus</i>	2X10 ⁷ cfu/g	-	-	-
14	Soil	<i>F. tularensis</i>	2X10 ⁷ cfu/g	-	-	-
15	Soil	<i>B. pseudomallei</i>	2X10 ⁷ cfu/g	-	-	-
16	Soil	Mixed <i>F. tularensis</i> + <i>B. pseudomallei</i>	2X10 ⁶ cfu/g each	-	-	-

565 ^aNucleic acid extract from these samples were investigated in the frame of SIBCRA exercises. Laboratory results were positive for all agents566 other than *B. anthracis* (i.e. *vaccinia virus*, *F. tularensis*, *B. pseudomallei*, and mixed *F. tularensis* and *B. pseudomallei*), ^bTo confirm that

567 DNA in the extract is amplifiable, samples were assessed using the 16S rRNA PCR. – not detected, + detected

568

569 Table 4: Swab samples tested in the field (PIONEX exercise, Pionki, Poland, project FP7
570 PRACTICE)

Sample	Type	Scenario	RPA results		qPCR results	
			BA_5345	<i>adk</i>	<i>purA</i>	<i>ptsI</i>
control 01	NTC	Nihil	-	-	-	-
control 02	Extraction	Nihil	-	-	-	-
control 03	BA 9602	Nihil	+	+	+	+
01	Swab	1	-	+	-	+
02	Swab	1	-	+	-	-
^a 03	Swab	1	-	-	-	-
^a 04	Swab	2	-	-	-	-
05	Swab	2	-	+	-	+
06	Swab	2	-	+	-	+
07	Swab	2	-	+	-	+
08	Swab	2	-	+	-	+
09	Swab	2	-	+	-	+
10	Swab	2	-	+	-	+
11	Swab	2	-	+	-	+
12	Swab	2	-	+	-	+
13	Swab	2	-	+	-	+

571 ^aSwab extracted samples were positive when assessed using the 16S rRNA PCR. – not detected, + detected

572

573

574

575

576

577

578

579

580

581

582 Table 5: Blind testing at the Institute of Veterinary Bacteriology, Bern, Switzerland

Strain	Sample type	^a Species	RPA			Identification
			BA_5345	<i>lef</i> (pXO1)	<i>capA</i> (pXO2)	
JF3788	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3786	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3852	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3787	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3785	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3784	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3853	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3854	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3783	DNA extract	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3960	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3965	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3966	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3963	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
JF3961	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
Chad A1	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
Chad A3	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
Chad A5	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
Chad A7	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
Chad A10	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
Chad A12	lysate	<i>B. anthracis</i>	+	+	+	<i>B. anthracis</i>
^b JF4875	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b JF5512	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b JF4075	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b M2841	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b JF5881	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b JF3778	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b JF1887	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b M2089	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b JF4090	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>
^b JF4059	DNA extract	<i>B. cereus</i>	-	-	-	<i>B. cereus</i>

583 ^aGenomic DNA characterized by realtime PCR Taqman assays targeting *sap* chromosomal, *cap*-pXO2 and *pag*-pXO1 genes, ^bEnd-point PCR584 of the *panC* gene confirmed the presence of amplifiable DNA in all negative samples (*B. cereus* group). – not detected, + detected

585

586

587







